2016 American Transplant Congress
Evaluation of the Long-Term Outcomes with Everolimus After Calcineurin Inhibitor Withdrawal: 36M Results of the H2304 and PROTECT Extension Studies.
Background: The H2304 and PROTECT studies demonstrated reduced nephrotoxicity with everolimus (EVR)-based calcineurin inhibitor (CNI; cyclosporine: CsA, tacrolimus: TAC)-free regimens at Month (M) 12. Here,…2016 American Transplant Congress
Reduced CMV Infection Using Single Low-Dose of Rabbit Anti-Thymocyte Globulin in Kidney Transplanted Recipients.
Hospital do Rim - UNIFESP, Sao Paulo, Brazil.
BACKGROUND: Cytomegalovirus (CMV) infection is associated with significant morbidity and mortality after solid organ transplantation and the historic incidence of our institution was 77%. Aiming…2016 American Transplant Congress
Safety, Efficacy, and Cost Saving Potential of Various Weight-Based Dosing for Thymoglobulin Induction Therapy in Kidney Transplant Recipients.
Introduction: There are limited data assessing the appropriate weight to use when dosing Thymoglobulin for induction therapy. The aim of this study is to assess…2016 American Transplant Congress
A Prospective Randomized, Comparative Trial of High-Dose Mizoribine versus Mycophenolate Mofetil in Combination with Tacrolimus and Basiliximab for Living Donor Renal Transplantation: A Multi-Center Trial.
PURPOSE: To compare the clinical outcomes of mizoribine (MZR; 12 mg/kg/day) and mycophenolate mofetil (MMF; 2000 mg/day) in combination with tacrolimus (FK), basiliximab (SIM), and…2015 American Transplant Congress
Assessment of Bleeding and Thrombosis in Responders and Initial Non-Responders to Aspirin After Continuous-Flow Left Ventricular Assist Device Placement
Medical University of South Carolina, Charleston, SC.
Purpose: This study evaluates bleeding and thrombosis following left ventricular assist device (LVAD) placement using platelet inhibition monitoring to determine responders to standard aspirin dosing…2015 American Transplant Congress
Comparison of Efficacy and Renal Function in KidneyTransplant Recipients Receiving Tacrolimus (TAC)-Based Immunosuppressive Regimens in Combination With Everolimus (EVR) or Mycophenolate (MPA)
1Nephrology, Hospital do Rim UNIFESP, Sao Paulo, Brazil; 2Pathology, UNIFESP, Sao Paulo, Brazil.
Introduction: Acute rejection and renal function are associated with long-term renal allograft survival. We evaluated these outcomes in patients receiving reduced TAC exposure combined with…2015 American Transplant Congress
Treatment With Everolimus and Reduced-Exposure Cyclosporine Is Efficacious in De Novo Renal Transplant Recipients at Increased Risk for Efficacy Failure: Post-Hoc Analysis from the A2309 Study
1For the A2309 Study Group, Italy; 2Novartis, Basel, Switzerland.
Purpose: Data is limited on the effect of everolimus (EVR) based regimens in renal transplant recipients (RTxR) who are at increased risk for rejection and…2015 American Transplant Congress
Factors Affecting Efficacy Outcomes at 12 and 24-Months After Kidney Transplantation in Patients from the A2309 Study
1Novartis, Basel, Switzerland; 2A2309 Study Group, Basel, Switzerland; 3Novartis, East Hanover, NJ.
Purpose: Efficacy outcomes post-transplantation are influenced by donor and recipient variables and interactions between them. Here, we present data from a multivariate analysis of risk…2015 American Transplant Congress
Electronic Health Service to Improve Therapeutic Drug Monitoring of Immunosuppressants
PurposeTherapeutic drug monitoring (TDM) of immunosuppressants is critical to avoid rejection or toxic side effects by under- or over-immunosuppression after heart transplantation (HTx). Hence, in…2015 American Transplant Congress
Efficacy of Low Dose Chemoprophylaxis for Coccidioidomycosis Infection in Liver Transplantation Recipients
Introduction:Coccidioidomycosis(CM) infection rate of 6.9% has been reported in solid organ transplantation recipients living in endemic Southwestern U.S.Aim:Assess the risk of CM infection in liver…
American Transplant Congress abstracts